Skip to main content
. 2014 Jan 1;34(1):60–65. doi: 10.1523/JNEUROSCI.3473-13.2014

Figure 1.

Figure 1.

CGRP potentiates ST-evoked IPSPs. A, Scheme showing stimulating (Stim.) and recording (circles) sites. B, Time course of CGRP effect on IPSPs (solid squares represent CGRP 0.5 μm; empty squares represent control cells). CGRP steadily increases ST-evoked IPSP amplitudes, and this effect outlasts the period of CGRP application. Insets on left, Examples of ST-evoked responses in a control cell (top) and one exposed to CGRP (bottom). Inset on top right, Examples of EPSPs isolated with picrotoxin (100 μm) before versus after a 10 min application of CGRP (1 μm). C, Top, Dose dependency of CGRP effect on IPSPs. After CGRP application (15 min), IPSP amplitudes increased to 260 ± 49% for 2 μm (n = 9, p = 0.002), 174 ± 22% for 1 μm (n = 4, p = 0.01), and 170 ± 15% for 0.5 μm (n = 5, p = 0.0005) of preapplication values. At a concentration of 250 nm CGRP had no significant effect (n = 8, p = 0.41). Eight cells were tested with no CGRP application. C, Bottom, Two CGRP receptor Type 1 antagonists reduced the effect of CGRP, compared with when CGRP (500 nm, n = 5) was applied alone (SB268262, 50 μm, n = 12, p < 0.001; 500 μm, n = 7, p < 0.01; CGRP8–37, 1 μm, n = 4, p < 0.001; 2 μm, n = 5, p = 0.01). AC, Anterior commissure; IC, internal capsule.